193 related articles for article (PubMed ID: 32437546)
1. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.
Yumeen S; Mirza FN; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf SR; Surovtseva YV; Foss FM; Girardi M
Blood Adv; 2020 May; 4(10):2213-2226. PubMed ID: 32437546
[TBL] [Abstract][Full Text] [Related]
2. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
3. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.
Kim SR; Lewis JM; Cyrenne BM; Monico PF; Mirza FN; Carlson KR; Foss FM; Girardi M
Oncotarget; 2018 Jun; 9(49):29193-29207. PubMed ID: 30018745
[TBL] [Abstract][Full Text] [Related]
4. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells.
Xu S; Ren J; Lewis JM; Carlson KR; Girardi M
J Invest Dermatol; 2023 Jul; 143(7):1322-1325.e3. PubMed ID: 36642402
[No Abstract] [Full Text] [Related]
5. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
7. The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.
Zhao L; Hsiao T; Stonesifer C; Daniels J; Garcia-Saleem TJ; Choi J; Geskin L; Rook AH; Wood GS
J Invest Dermatol; 2022 Dec; 142(12):3253-3261.e4. PubMed ID: 35787399
[TBL] [Abstract][Full Text] [Related]
8. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
12. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
13. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.
Yu X; Li H; Zhu M; Hu P; Liu X; Qing Y; Wang X; Wang H; Wang Z; Xu J; Tan R; Guo Q; Hui H
J Invest Dermatol; 2020 Oct; 140(10):2009-2022.e4. PubMed ID: 32119867
[TBL] [Abstract][Full Text] [Related]
16. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
[TBL] [Abstract][Full Text] [Related]
17. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
18. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
19. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
Damsky WE; Choi J
Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
[TBL] [Abstract][Full Text] [Related]
20. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]